Evaluation of the Efficacy of Radiofrequency in the Treatment of Renal Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

310 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-10-31

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Multi-institutional registry on a cohort of 310 patients with biopsy-proven renal cell carcinoma treated by Radiofrequency ablation. All patients will be included consecutively and retrospectively in all centers to obtain the required number of patient followed during 5 years.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparison Between Surgery and Radiofrequency for Treatment of Renal Tumors

NCT00221728

Kidney Neoplasms

TERMINATED PHASE2/PHASE3

RF Ablation of Treatment of Metastatic Lesions in Patients Undergoing Antiangiogenic Therapy for Stage IV Renal Cell Carcinoma

NCT00601120

Renal Cell Carcinoma

WITHDRAWN NA

Radiofrequency Interstitial Tissue Ablation in Treating Patients With Localized Renal Cell Carcinoma (Kidney Cancer)

NCT00019955

Kidney Cancer

COMPLETED PHASE2

Radiofrequency Ablation of Lung Tumors

NCT00180856

Lung Cancer Metastasis

COMPLETED PHASE2

Air Dissection in Percutaneous Radiofrequency Ablation of T1a Renal Cell Carcinoma

NCT03395379

Unrecognized Condition

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Radiofrequency ablation (RFA) of renal cell carcinoma (RCC) is actually used in elderly patients with small renal tumors (diameter ≤ 4 cm) and presenting a high risk of surgery (due to co-morbidity) and/or reduced renal function. RFA is a minimally invasive technique, considered as an alternative to surgery to limit morbidity and to preserve kidney function. The technique is well known and has proven his efficacy for the treatment of small tumors.

An enlargement of the indications of RFA to patient without contra-indication to surgery will depend on the efficacy of the technique.

The main objective of the study is to evaluate the local efficacy of the ablation based on the technical success, and on the evaluation of local cancer recurrence over 5 years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Renal Cell Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

patients

Treated by percutaneous image-guided radiofrequency for renal tumor

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient treated with percutaneous RFA
* Patient with diagnosis of renal masses with a maximum of 3 masses treated during the ablation
* The diameter of the tumor must be ≤ 40 mm, characterized by CT-scan or MRI
* The histology of the tumor must be biopsy-proven or the patient must have previous surgical ablation of renal tumor (ipsi or contralateral)

Exclusion Criteria

* Patient treated by surgery or laparoscopy
* Benign tumors
* No histological diagnosis (no biopsy or no previous treated renal carcinoma)
* Patient having secondary malignant sites, ganglions or visceral metastatic cells or endo-venous extend at the time of RFA
* Patient having a diagnosis of primary or secondary extra-renal tumor location and not into remission
* Patients treated with antiangiogenic drugs during the 6 months prior RFA.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No